Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05064176
Other study ID # KCE19-1245
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2022
Est. completion date December 2026

Study information

Verified date February 2022
Source Universitaire Ziekenhuizen Leuven
Contact Nele Devoogdt
Phone 0032 16 34 25 15
Email nele.devoogdt@kuleuven.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this research proposal is to investigate - in patients with lymphoedema of the upper limb or lower limb (P) - the added value of reconstructive lymphatic surgery (I) - to the decongestive lymphatic therapy (usual care) (C) - on the lymphoedema-specific quality of life (QoL) (O) - at 18 months post-surgery/ no surgery (T) Consequently, a multicentre pragmatic randomised controlled trial is performed to give an answer on following research question: 'Is, in addition to usual care - i.e. decongestive lymphatic therapy -, reconstructive lymphatic surgery (intervention group) superior to no surgery (control group), for the treatment of upper or lower limb lymphoedema?'


Description:

Lymphoedema is a chronic and often debilitating condition caused by lymphatic insufficiency. It leads to swelling of the limb and an increased risk of infection. It can be classified as primary (congenital) or secondary (acquired) lymphoedema. Lymphoedema is very burdensome for the patient and therefore is it often associated with mental problems for example frustration and stress. In addition, because of the increase in volume of the limb, patients also develop physical problems, such as pain, heaviness, loss of strength, and develop functional problems, such as problems with household, mobility or social activities. These mental, physical and functional problems all have a negative impact on quality of life and have an influence on the ability to work. Consensus exist that the first choice of treatment is a conservative treatment. This conservative treatment consists of skin care, compression therapy (i.e. multilayer bandaging and compression garments), exercises and lymph drainage. Reconstructive lymphatic surgery is another option, also often performed: i.e. lymphovenous anastomoses, on the one hand, and a lymph node transfer, on the other hand. By (partially) restoring the lymphatic transport, the reconstructive lymphatic surgery may possibly lead to a larger decrease of the lymphoedema volume and therefore greater discontinuation of the compression garment. Consequently, patients will have an improvement in functioning and quality of life. Currently, scientific evidence for reconstructive lymphatic surgery for the treatment of lymphoedema is missing. Therefore, the aim of this trial is to investigate the added value of reconstructive lymphatic surgery of the lymphatic system in addition to the conservative treatment, for the treatment of lymphoedema.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date December 2026
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Unilateral or bilateral, primary or secondary lymphoedema of the upper or lower limb - If cancer-related lymphoedema, approval for participation in study from oncological specialist (patient participation has to be discussed during Multidisciplinary Oncological Consult); approval if: - estimated cancer-related survival is =3 years - oncological safety is guaranteed: for instance, time interval since radiotherapy/ chemotherapy is =3 months - Lymphoedema stage 1 to 2b - Objective diagnosis of lymphoedema: = 5% volume difference OR = 2 minor/ 1 major criteria on lymphoscintigraphy OR presence of IndoCyanineGreen (ICG) dermal backflow - Score on Lymph-ICF questionnaire at screening: = 25 / 100 (= moderate level of problems in functioning related to the development of lymphoedema) - History of at least 6 months of decongestive lymphatic therapy (DLT) until minimal pitting - Age = 18 years Exclusion Criteria: - Participants with history of liposuction, lymphovenous anastomosis, lymph node transfer - Pregnant participants - Severe obese participants: BMI>35 - Estimated cancer-related survival is <3 years and oncological safety is not guaranteed (e.g. interval since radiotherapy/ chemotherapy is <3 months) - In case of lower limb lymphoedema: presence of chronic venous insufficiency C4, C5, C6; deep venous thrombosis; post-thrombotic syndrome - Allergy for ICG, iodine, penicillin and sulphonamides; increased activity of thyroid gland; benign tumour in thyroid; heparin use and severe renal insufficiency

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Usual care
Home physical therapist performs usual care and educates the patient to perform self-management Usual care: M1-6: 6 months of maintenance decongestive lymphatic therapy (DLT) (by patient and home physical therapist): week 1-2: no physical therapy; patient performs limb elevation, muscle contractions and wears the bandage (intervention group)/ compression garment (control group) week 3-4: start physical therapy, 2 days/ week: exercises, skin care & manual lymph drainage (MLD), education; self-management by patient and wearing compression garment 14-16h/day (4 sessions) M2-6: 1 day/ week physical therapist: exercises, skin care & MLD, and self-management by patient and wearing compression garment 14-16h/day (20 sessions) M7-12: 6 months of maintenance DLT by patient (self-management) and home physical therapist: - 1 day/week physical therapist: skin care, MLD, exercises (26 sessions) Month 13-18: 6 months of maintenance DLT by patient Month 19-36: 18 months of follow-up
Procedure:
Reconstructive lymphatic surgery
For the procedure of LVA: - Aim: making anastomoses of lymph vessels at the capillary level with a diameter of 0.3 to 0.8 mm, to redirect lymph to venous stream directly For the procedure of LNT: - Aim: Placed lymph nodes act as sponge to absorb lymphatic fluid and direct it into the vascular network; Placed lymph nodes induce lymphangiogenesis

Locations

Country Name City State
Belgium Ghent University Hospital Gent
Belgium University Hospitals of Leuven, center for lymphedema Leuven
Belgium CHU-UCL Mont-Godinne Namur

Sponsors (1)

Lead Sponsor Collaborator
Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lymphoedema-specific QoL (or problems in functioning related to development of lymphoedema) evaluated with the Dutch or French version of the Lymph-ICF questionnaire for upper or lower limb lymphoedema at 18 months
Secondary Lymphoedema-specific QoL (or problems in functioning related to development of lymphoedema) evaluated with the Dutch or French version of the Lymph-ICF questionnaire for upper or lower limb lymphoedema at 1, 3, 6, 12 (short term) and 24, 36 (longer term) months
Secondary General health-related QoL evaluated with the EuroQol-5D-5L questionnaire at 1, 3, 6, 12, 18, 24, 36 months
Secondary Limb volume evaluated using circumference measures (ml) at 1, 3, 6, 12, 18 (key secondary outcome), 24, 36 months
Secondary Failure to reduce the hours a day of wearing the compression stocking failure is defined as not able to continue the reduction of the hours of wearing the compression garment as stated by the protocol at 12, 18, 24, 36 months
Secondary The hours of wearing the compression garment during one week evaluated with the International Compression Club (ICC) questionnaire ('dosage score' between 0-168h) at 12, 18 (key secondary outcome), 24, 36 months
Secondary The experience of the compression garment evaluated with the International Compression Club (ICC) questionnaire ('comfort score' between 0-10 and 'complication score' between 0-10) at 1, 3, 6, 12, 18, 24, 36 months
Secondary The physical activity level evaluated with the International Physical Activity Questionnaire (IPAQ) - short form (MET-hours/week) at 1, 3, 6, 12, 18, 24, 36 months
Secondary The need for intensive treatment due to an increase in lymphoedema volume through interview at 6, 12, 18, 24, 36 months
Secondary Body weight measured using a balance at 1, 3, 6, 12, 18, 24, 36 months
Secondary Work capacity evaluated with the Work Productivity and Activity Impairment (WPAI-GH) questionnaire at 1, 3, 6, 12, 18, 24, 36 months
Secondary Work ability evaluated with the Quickscan 18 (short form) questionnaire at 1, 3, 6, 12, 18, 24, 36 months
Secondary Infection during the previous 18 months (yes/no) through interview at 18, 36 months (adverse events are collected during each clinical assessment but the amount of infections as secondary outcome are taken together for statistical analyses per 18 months)
Secondary Complications of surgery through interview at 1, 3, 6, 12, 18, 24, 36 months
Secondary Recurrence of cancer (yes/no) through medical file at 36 months
Secondary Lymphatic transport through lymphoscintigraphy at 18 months
Secondary Costs related to lymphoedema and its treatment during previous 18 months through interview at 18, 36 months
See also
  Status Clinical Trial Phase
Completed NCT05507346 - A Clinical Study to Evaluate the Effectiveness of a Novel Portable Non-Pneumatic Active Compression Device vs. an Advanced Pneumatic Compression Device for Treating Lower Extremity Lymphedema N/A
Completed NCT06067880 - Surgical Intervention and Lymphatic Diseases.
Recruiting NCT04797390 - A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema N/A
Completed NCT02676752 - Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis
Completed NCT06323200 - Lymphedema Duration on Lymphatic Vessel Quality and Outcomes After LVA
Completed NCT02506530 - Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema N/A
Completed NCT02253186 - Clinical Study to Assess Safety and Efficacy of a New Armsleeve in the Management of Arm Lymphoedema N/A
Terminated NCT02020837 - A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema Early Phase 1
Recruiting NCT01318785 - Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications Phase 2
Enrolling by invitation NCT02375165 - Biomarkers for the Detection of Lymphatic Insufficiency
Completed NCT00852930 - Low Level Laser Treatment and Breast Cancer Related Lymphedema Phase 4
Completed NCT02308488 - Study of Prone Accelerated Breast And Nodal IMRT N/A
Completed NCT01112189 - Use of Stem Cells in Lymphedema Post Mastectomy Phase 1/Phase 2
Completed NCT00743314 - Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer Early Phase 1
Recruiting NCT06237907 - Pyroptosis and Ferroptosis in the Pathophysiology of Lymphedema
Terminated NCT01580800 - National Breast Cancer and Lymphedema Registry
Suspended NCT05366699 - LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy N/A
Completed NCT06249360 - Lymphatic System Reflux After Lymphatic Operation
Completed NCT06220903 - The Effect of Complex Decongestive Therapy in Patients With Lymphedema N/A
Terminated NCT02923037 - Hatha Yoga in Breast Cancer Survivors N/A